Nuvation Bio (NUVB) Expected to Announce Earnings on Wednesday

Nuvation Bio (NYSE:NUVB - Get Free Report) is projected to announce its Q1 2025 earnings results after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $0.42 million for the quarter.

Nuvation Bio Trading Up 8.4 %

NUVB stock traded up $0.19 during mid-day trading on Friday, hitting $2.46. 5,897,209 shares of the company were exchanged, compared to its average volume of 2,136,444. The firm has a fifty day simple moving average of $1.96 and a 200 day simple moving average of $2.37. The company has a market capitalization of $833.15 million, a PE ratio of -1.13 and a beta of 1.47. Nuvation Bio has a twelve month low of $1.54 and a twelve month high of $3.97.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on NUVB shares. JMP Securities assumed coverage on shares of Nuvation Bio in a report on Wednesday, April 23rd. They issued a "market outperform" rating and a $6.00 price target for the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $10.00 target price (up from $6.00) on shares of Nuvation Bio in a report on Tuesday, January 7th. HC Wainwright dropped their price target on Nuvation Bio from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. Citizens Jmp initiated coverage on Nuvation Bio in a research report on Wednesday, April 23rd. They set a "mkt outperform" rating and a $6.00 price objective for the company. Finally, Wedbush reaffirmed an "outperform" rating and issued a $5.00 target price on shares of Nuvation Bio in a research report on Thursday, March 27th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Nuvation Bio currently has a consensus rating of "Buy" and a consensus target price of $7.83.

Insider Activity

In related news, CEO David Hung acquired 200,000 shares of the company's stock in a transaction dated Friday, April 4th. The shares were bought at an average price of $1.66 per share, for a total transaction of $332,000.00. Following the acquisition, the chief executive officer now owns 58,481,054 shares in the company, valued at $97,078,549.64. This trade represents a 0.34 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 29.93% of the stock is currently owned by company insiders.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.